Clinical trials: Pancreatic Cancer Stage II
Pancreas Cancer
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
Efficacy and safety of a supportive treatment with European mistletoe extract Iscador® Qu ("quercus", i.e. from oak tree) in patients with pancreatic cancer (Union for International Cancer Control, UICC stages II-IV), in addition…
- Trial name
- NCT01448668
- Where
- 9 sites in Austria, Germany
- Volunteers
- 220 people
- Sponsor
- IFAG AG
Advanced Solid Tumors, Glioblastoma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
- Conditions
- Advanced Solid Tumors, Glioblastoma, Soft Tissue Sarcoma (Excluding GIST), Endometrial Carcinoma
- Trial name
- NCT02611024
- Testing
- Lurbinectedin, Irinotecan
- Where
- 23 sites in United States, France and 4 more
- Volunteers
- 316 people
- Sponsor
- PharmaMar
Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Conditions
- Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
- Trial name
- NCT03600233
- Testing
- CVM-1118
- Where
- 8 sites in Taiwan
- Volunteers
- 34 people
- Sponsor
- TaiRx, Inc.
Pancreatic Neoplasms
Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer
The purpose of this study is to compare the effectiveness of gemcitabine with or without tipifarnib (R115777) in patients who have advanced pancreatic cancer.
- Trial name
- NCT00005648
- Testing
- Gemcitabine with R115777
- Volunteers
- 688 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pancreatic Cancer
A Study of ABTL0812 in Pancreatic Cancer
A Randomized Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy.
- Trial name
- Pancreatic (NCT03417921)
- Testing
- ABTL0812, Gemcitabine and nab-paclitaxel
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Ability Pharmaceuticals SL
Pancreatic Neoplasms
GEMOX: Oxaliplatin in Pancreatic Cancer
Primary objective: To evaluate overall response rate (based on RECIST criterion) Secondary objective: To evaluate time to progression, clinical benefit, quality of life and safety
- Trial name
- NCT00261092
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Sanofi
Pancreatic Neoplasms
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
This study is being conducted to evaluate the clinical efficacy, biologic activity (inhibition of PX-12 target thioredoxin-1) and effects of an expired metabolite of PX-12 in patients with advanced pancreatic cancer.
- Trial name
- NCT00417287
- Testing
- PX-12
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cascadian Therapeutics Inc.
Pancreatic Cancer
A Safety Study Using Pentamidine in Patients With Pancreatic Cancer Undergoing Standard Therapy
The purpose of this study is to investigate the safety and possible efficacy of the use of pentamidine in the treatment of pancreatic cancer metastasis in subjects receiving standard therapy.
- Trial name
- NCT00810953
- Testing
- Pentamidine
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Oncozyme Pharma Inc.
Pancreatic Neoplasms
Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies
This study is a Phase I/II study. In Phase I of this study, the objective is to determine the maximum tolerated dose (MTD) of combination therapy with Aroplatin and gemcitabine (Gemzar®) in subjects with unresectable, locally…
- Trial name
- NCT00081549
- Testing
- Aroplatin (Liposomal NDDP, L-NDDP)
- Volunteers
- 111 people
- Sponsor
- Aronex Pharmaceuticals
Adenocarcinoma, Metastasis
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
The intention of this trial is to evaluate safety and efficacy of a combination treatment of EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.
- Conditions
- Adenocarcinoma, Metastasis, Pancreas Neoplasms
- Trial name
- NCT00377936
- Testing
- Gemcitabine alone, EndoTAG-1 and Gemcitabine
- Where
- 3 sites in Czechia, Hungary and 1 more
- Volunteers
- 212 people
- Sponsor
- MediGene
Pancreatic Cancer
Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer
The goal of the adaptive trial design is to determine the over-all safety of escalating doses of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the significant clinical benefits required to…
- Trial name
- NCT00504998
- Testing
- Rexin-G
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Epeius Biotechnologies
Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
The purpose of this study is to determine if gastric/esophageal, lung, pancreatic, bladder and sarcoma patients show benefit from brivanib treatment. Patients who clearly do, stay on treatment.
- Conditions
- Advanced Non-small Cell Lung Cancer, Transitional Cell Carcinoma, Soft Tissue Sarcoma, Gastric/Esophageal Adenocarcinoma
- Trial name
- NCT00633789
- Testing
- brivanib
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 597 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Neoplasm
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer
Antroquinonol is proposed for the treatment of neoplasms. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve…
- Trial name
- NCT03310632
- Testing
- Antroquinonol
- Where
- 11 sites in United States, South Korea and 1 more
- Volunteers
- 55 people
- Sponsor
- Golden Biotechnology Corporation
Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer.
- Trial name
- NCT01472198
- Testing
- Simtuzumab, Gemcitabine
- Where
- 57 sites in United States, Russia
- Volunteers
- 250 people
- Sponsor
- Gilead Sciences
Solid Tumor, Pancreatic Adenocarcinoma
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of OBI-3424 administered as a single agent.
- Trial name
- NCT03592264
- Testing
- OBI-3424
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- OBI Pharma, Inc
Pancreatic Cancer
Investigator's Initiated Phase II Study for Pancreatic Cancer Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of TL-118 alone or in combination with pancreatic cancer chemotherapy.
- Trial name
- NCT01659502
- Testing
- TL-118
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Tiltan Pharma Ltd.
Tumors With CDK4/6 Pathway Activation
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.
- Trial name
- SIGNATURE (NCT02187783)
- Testing
- LEE011
- Where
- 61 sites in United States
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Pancreatic Cancer
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid…
- Trial name
- NCT06821503
- Testing
- LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound)
- Where
- 16 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Pancreatic Cancer
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
- Trial name
- NCT00326911
- Testing
- cetuximab, bevacizumab, gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Advanced Adenocarcinoma of Pancreas
A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
The main objective of this study is to assess the biological activity of CP-4126 in patients with advanced pancreatic cancer. In addition, the correlation between hENT1 (human equilibrative nucleoside transporter 1) and overall…
- Trial name
- NCT00913198
- Testing
- IV CP-4126
- Where
- 3 sites in Belgium, Norway
- Volunteers
- 21 people
- Sponsor
- Clavis Pharma